$DSGN News
Last published 1w ago
- 1w agoDSGNDesign Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoDSGNDesign Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business UpdatesGlobeNewswireDT-216P2 Anticipated Milestones: Registrational Plan Update in Q4 2026 and 12-Week RESTORE-FA Data in Q1 2027 Cash and securities of $208.6 million at quarter-end provide strong financial runway CARLSBAD, Calif.,
- 2mo agoDSGNDesign Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewswireCARLSBAD, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced
- 3mo agoDSGNDesign Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial ResultsGlobeNewswireRESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027 Patient dosing initiated in Phase 1 multiple-ascending dose trial of
- 4mo agoDSGNDesign Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1GlobeNewswireGeneTAC® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1 CARLSBAD, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc.
- 5mo agoDSGNDesign Therapeutics to Participate in 2026 Jefferies Global Healthcare ConferenceGlobeNewswireCARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that
- 5mo agoDSGNDesign Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich AtaxiaGlobeNewswireDT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endogenous frataxin mRNA and protein after four weeks of intravenous dosing DT-216P2 generally well-tolerated Data support
- 5mo agoDSGNDesign Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich's Ataxia on Monday, May 18, 2026GlobeNewswireCARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data
- 6mo agoDSGNDesign Therapeutics Announces First Quarter 2026 Financial Results and Recent Business UpdatesGlobeNewswireAdditional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and Regulatory Expertise Cash and Securities of
- 8mo agoDSGNDesign Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business UpdatesGlobeNewswireTrials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 Cash and Securities of $219.8 Million as of Year-End Supports Ongoing Clinical Execution
- 8mo agoDSGNDesign Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireCARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that
- 11mo agoDSGNDesign Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireCARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that
- 1y agoDSGNDesign Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial ResultsGlobeNewswireObtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1) Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs Endothelial Corneal
- 1y agoCMPSDSGNXENEDesign Therapeutics Appoints Justin Gover to Board of DirectorsGlobeNewswireCARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the
- 1y agoDSGNDesign Therapeutics, Inc. (DSGN) Presents at Cantor Global Healthcare Conference 2025 TranscriptEarnings Call Transcripts
- 1y agoDSGNDesign Therapeutics to Participate in the 2025 Cantor Global Healthcare ConferenceGlobeNewswireCARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that
- 1y agoDSGNDesign Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial ResultsGlobeNewswireEarly Human Pharmacokinetics Data for DT-216P2 Demonstrates Favorable Translation from Non-Human Primates (NHPs) to Humans and Improved DT-216 Product Profile for Friedreich Ataxia (FA) Program RESTORE-FA Phase 1/2
- 1y agoDSGNDesign Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2GlobeNewswireInitial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Has Demonstrated Favorable Safety and Pharmacokinetics IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; Notice Received
- 1y agoDSGNDesign Therapeutics to Participate in 2025 Jefferies Global Healthcare ConferenceGlobeNewswireCARLSBAD, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that
- 1y agoDSGNDesign Therapeutics to Participate in 2025 RBC Capital Markets Healthcare ConferenceGlobeNewswireCARLSBAD, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that
- 1y agoDSGNDesign Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial ResultsGlobeNewswirePhase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program Well-Capitalized with Cash
- 1y agoDSGNDesign Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal DystrophyGlobeNewswireCARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced
- 1y agoDSGNDesign Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025GlobeNewswireCARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that
- 1y agoDSGNDesign Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical OfficerGlobeNewswireCARLSBAD, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the
- 1y agoANABDSGNPSTXXERS+1Bright Peak Therapeutics Appoints John Schmid to its Board of DirectorsGlobeNewswireSAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer,
- 1y agoDSGNDesign Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireInitiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025 Dosing Complete in DT-168 Phase 1 Healthy Volunteer Trial, with Data on Track
- 1y agoDSGNDesign Therapeutics to Participate in Leerink's Global Healthcare ConferenceGlobeNewswireCARLSBAD, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that
- 1y agoDSGNDesign Therapeutics to Participate in Multiple Upcoming Investor ConferencesGlobeNewswireCARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that
- 2y agoDSGNDesign Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM PortfolioGlobeNewswireFuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the First Half of 2025 Friedreich Ataxia (FA) Program on Track to Initiate Phase 1 Single Ascending Dose, Healthy Volunteer Study
- 2y agoDSGNDesign Therapeutics to Participate in the 2024 Cantor Global Healthcare ConferenceGlobeNewswireCARLSBAD, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management
- 2y agoDSGNDesign Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ PortfolioGlobeNewswireFriedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Advancing Toward Clinical Trials Active Research Pipeline with Programs Progressing in Myotonic Dystrophy Type-1 (DM1) and
- 2y agoDSGNDesign Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program MilestonesGlobeNewswireAdvancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling
- 2y agoDSGNDesign Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare ConferenceGlobeNewswireCARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will
- 2y agoDSGNDesign Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoDSGNDesign Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswireNew Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025 IND
- 2y agoDSGNDesign Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio UpdateGlobeNewswireCARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company
- 2y agoDSGNDesign Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024GlobeNewswireSeasoned Biotech Executive Pratik Shah Appointed as Chief Executive Officer to Lead Company Turnaround Current Cash and Securities of ~$290M Support Extended Five-Year Operating Runway Through 2028 Revised Corporate
- 3y agoDSGNDesign Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial ResultsGlobeNewswireInitial Data from Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Showed Significant Increase in FXN mRNA Levels in Skeletal Muscle Company Expects to Resume a Multiple Dose Phase 1 Clinical Study
- 3y agoDSGNDesign Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich AtaxiaGlobeNewswireDT-216 Resulted in a Significant Increase in FXN mRNA Levels in Skeletal Muscle of FA Patients Treatment Generally Well-Tolerated; Injection Site Reactions Attributable to Current Formulation Composition Design Plans
- 3y agoDSGNDesign Therapeutics to Present at the 2023 Jefferies Healthcare ConferenceGlobeNewswireCARLSBAD, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported that
- 3y agoDSGNDesign Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial ResultsGlobeNewswireInitial Data from Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Expected in the Third Quarter of 2023 Progress Across GeneTAC™ Small Molecule Pipeline with IND Submissions for FECD and
- 3y agoDSGNDesign Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023GlobeNewswireTreatment with DT-168 Eye Drops Reduced Nuclear Foci and Significantly Improved Mis-Splicing In Vitro Company On-track to Submit Investigational New Drug Application for DT-168 in the Second Half of 2023 CARLSBAD,
- 3y agoDSGNDesign Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewswirePhase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Ongoing with Data Expected Mid-Year Continued Progress Across Pipeline of GeneTAC™ Small Molecules with Three Programs Expected to be in
- 3y agoDSGNDesign Therapeutics to Participate in the SVB Securities Virtual Global Biopharma ConferenceGlobeNewswireCARLSBAD, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that
- 3y agoDSGNDesign Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio ProgressGlobeNewswireDT-216 was Generally Well-Tolerated and Resulted in a More than Doubling of Frataxin mRNA in Patients with Friedreich Ataxia Second GeneTACTM Development Candidate, DT-168, Selected for the Treatment of Fuchs
- 4y agoDSGNDesign Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial ResultsGlobeNewswireInitial Data from Single-Ascending Dose Phase 1 Trial of DT-216 for Friedreich Ataxia Expected to be Reported in December 2022 Dosing Initiated in the Multiple-Ascending Dose Phase 1 Trial of DT-216; Trial Completion
- 4y agoDSGNDesign Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022GlobeNewswireCARLSBAD, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that
- 4y agoDSGNDesign Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine SummitGlobeNewswireCARLSBAD, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported that João Siffert, M.D., president and
- 4y agoDSGNDesign Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial ResultsGlobeNewswireInitial Data from Friedreich Ataxia Phase 1 Trial of DT-216 Expected in the Fourth Quarter of 2022 Strong Financial Position with $359.4 Million in Cash and Securities to Support Multi-Year Operating Runway CARLSBAD, Calif., Aug. 08, 2022 (GLOBE
- 4y agoDSGNDesign Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare ConferenceGlobeNewswireCARLSBAD, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that João Siffert, M.D., president and